PhrmaSec Limited is a biotech company in pursuit of the clinical situations associated with hormonal dysregulation. Using an innovative approach, PhrmaSec identifies the therapeutic molecules that target members of an import family of hormone receptors, namely G-protein coupled receptors (GPCRs).
Researches led by Professor Billy Chow and other groups have demonstrated GPCRs are involved vast physiological functions and making the GPCRs very attractive drug targets to modulate the pathological body conditions and develop curative of disease. However, the identification of GPCRs targeting molecules has never been easy, until PhrmaSec has developed its state-of-the-art technology making the high-throughput in-silico screening possible. This innovation is later translated into crucial pharmacophore development and identification of crucial small compound modulators for specific receptors.
The University of Hong Kong
The Chinese University of Hong Kong